Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most mechanistic/indication statements are supported, and several safety claims align with boxed warning content (serious infections, TB; GI perforation; neutropenia; liver enzyme/lipid abnormalities). However, multiple efficacy/statistical claims (ACR, MONARCH outcome details) and several non-label development/patent/biologic-availability statements are not supported by the provided label text, and some administration/monitoring timing/clinical-response timing statements are unsupported.
Category Scores
Accurate Statements
KEVZARA is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more DMARDs.
Label Section 1.1 Rheumatoid Arthritis (RA).
Sarilumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and inhibits IL-6-mediated signaling through these receptors.
Label Section 12.1 Mechanism of Action.
Serious risks of Kevzara include serious infections.
Label Warning: RISK OF SERIOUS INFECTIONS; and Adverse Reactions serious reactions list (Serious infections).
Serious risks of Kevzara include tuberculosis.
Label Warning (Reported infections include Active tuberculosis...).
Serious risks of Kevzara include gastrointestinal perforations.
Label Adverse Reactions serious reactions list (Gastrointestinal perforation) and Warning Section 5.3 Gastrointestinal Perforation.
Serious risks of Kevzara include neutropenia.
Label Adverse Reactions serious reactions list (Neutropenia...).
Kevzara has a boxed warning for infections.
Label shows WARNING: RISK OF SERIOUS INFECTIONS.
Kevzara has elevated liver enzymes.
Label Adverse Reactions serious reactions list includes elevated liver enzymes; and Warning/precautions references laboratory abnormalities (5.2).
Unsupported Statements
In the MOBILITY study, 58% of patients on Kevzara 200 mg plus methotrexate achieved an ACR20 response at week 24.
Provided label excerpts do not include MOBILITY trial ACR20 numerical results.
In the MOBILITY study, 44% of patients on placebo plus methotrexate achieved an ACR20 response at week 24.
Provided label excerpts do not include MOBILITY trial ACR20 numerical results.
In the MOBILITY study, about 30% of patients achieved an ACR50 response.
Provided label excerpts do not include MOBILITY trial ACR50 numerical results.
In the MOBILITY study, about 17% of patients achieved an ACR70 response.
Provided label excerpts do not include MOBILITY trial ACR70 numerical results.
Radiographic data in the MOBILITY study confirmed Kevzara inhibited joint damage over two years.
Provided label excerpts do not include radiographic/joint damage duration results.
In the MONARCH study, more Kevzara patients (44% vs 33%) reached low disease activity or remission at week 24.
Provided label excerpts do not include MONARCH trial numerical outcomes.
In the MONARCH study, the low disease activity or remission outcome was reached without needing methotrexate.
Provided label excerpts do not support this specific trial design/outcome interpretation.
In head-to-head trials against adalimumab (Humira), Kevzara outperforms placebo.
Provided label excerpts do not discuss adalimumab head-to-head results nor support 'outperforms placebo' in that context.
Common side effects of Kevzara include upper respiratory infections (29%).
Provided label excerpts do not list upper respiratory infection incidence percentages.
Common side effects of Kevzara include injection site reactions (10%).
Provided label excerpts do not list injection site reaction incidence percentages.
Kevzara can cause elevated liver enzymes.
Supported in general (elevated liver enzymes as serious/lab abnormality), but the claim is not tied to the specific phrasing 'can cause' with specific incidence; still supported that elevated liver enzymes occur. (No quantitative support required for 'can cause'.) This item is treated as supported elsewhere; if scored as unsupported, it would be due to lack of incidence—however the label supports the occurrence.
Kevzara has a black box warning for malignancy risk.
Provided label excerpts show only a WARNING: RISK OF SERIOUS INFECTIONS and do not provide any boxed/black box statement for malignancy risk.
Patients should monitor lipids regularly while taking Kevzara.
Provided label excerpts mention lipid abnormalities as serious adverse reactions but do not state a monitoring instruction.
Patients should monitor liver function regularly while taking Kevzara.
Provided label excerpts reference liver enzyme abnormalities and dosage modification, but do not include an explicit monitoring instruction in the provided text.
Many patients notice improvement in pain and stiffness within 2-4 weeks after starting Kevzara.
Provided label excerpts do not include onset-of-symptom improvement timing.
Full ACR responses with Kevzara peak around 12-24 weeks.
Provided label excerpts do not include ACR time-course information.
If there is no benefit by week 12, doctors reassess.
Provided label excerpts do not include a week-12 reassessment instruction.
In trials, Kevzara worked in 40-50% of TNF non-responders.
Provided label excerpts do not include this statistic.
Kevzara is not for mild RA.
Provided label excerpt specifies 'moderately to severely active' but does not explicitly state 'not for mild RA' as a labeled statement.
Kevzara is not used as monotherapy without methotrexate in the stated trial context.
Provided label excerpt explicitly allows monotherapy (Section 2.2: may be used as monotherapy), so the claim is not supported as a general statement (and the label excerpt does not support this trial-context limitation).
Sanofi and Regeneron co-developed Kevzara.
No development/co-development information is included in the provided label excerpts.
No biosimilars for Kevzara have been approved yet.
No biosimilar approval status information is included in the provided label excerpts.
U.S. patents for Kevzara expire around 2032.
No patent/expiration information is included in the provided label excerpts.
Some formulation patents for Kevzara expire around 2036.
No patent/expiration information is included in the provided label excerpts.
Contradictions
High
AI Statement
Kevzara is not used as monotherapy without methotrexate in the stated trial context.
Label Reference
Label Section 2.2 Recommended Dosage for Rheumatoid Arthritis: 'KEVZARA may be used as monotherapy or in combination with methotrexate (MTX) or other conventional DMARDs.'
Important Omissions
Dosage and administration details (e.g., 200 mg once every two weeks subcutaneous injection) were not assessed in the provided AI claims list except implicitly; no claim explicitly stated the labeled dose/frequency.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported efficacy percentages and trial interpretations could mislead benefit expectations. The contradictory statement about monotherapy could affect appropriate labeled use context. Monitoring instructions for lipids and liver function were not explicitly supported by provided label excerpts. However, major safety warnings (serious infections, TB, neutropenia, GI perforation) align with labeling content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several efficacy statistics and multiple non-label policy/development/patent/biosimilar claims were not supported by the provided prescribing information. Also, one statement contradicts the label regarding monotherapy availability.
Suggested Improvement
Limit claims to what is present in the provided label excerpts (indication, mechanism, labeled safety warnings/serious adverse reactions, and labeled dosing/monotherapy allowance). Remove or qualify unsupported trial-specific percentages, onset timing, and all non-label development/patent/biosimilar assertions unless supported by the provided labeling text.